Reply to progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|11|1906-1907

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.11, 2015-06, pp. : 1906-1907

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1906

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression‐free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 7-10

John Wiley & Sons Inc

Access to resources Recommend Favorite

Progression‐free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma

By  

CANCER, Vol. 120, Iss. 1, 2014-01 ,pp. : 52-60

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials

By  

CANCER, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

John Wiley & Sons Inc

Access to resources Recommend Favorite

Relationship between Treatment Effects on Progression-Free Survival and Overall Survival in Multiple Myeloma: A Systematic Review and Meta-Analysis of Published Clinical Trial Data

By  

Oncology Research and Treatment, Vol. 38, Iss. 3, 2015-02 ,pp. : 88-94

Karger

Access to resources Recommend Favorite